ASH 2022: Brukinsa Bests Imbruvica In Leukemia/Lymphoma PFS
Adds To ORR Benefits Shown Earlier
Two years after missing its primary endpoint in a different indication, BeiGene’s bet on a second Phase III head-to-head study with its BTK inhibitor Brukinsa have finally paid off, with PFS benefits demonstrated over rival Imbruvica.
